Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02215265 · ClinicalTrials.gov registry record · Phase 3
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
A Phase 3 study of Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer, sponsored by Lisette Nixon.
- Active
- Registry status
- Phase 3
- Development phase
- 1,269
- Enrollment target
- 20
- Study locations
NCT02215265 is a Phase 3 study of Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer that is active but no longer recruiting, run by Lisette Nixon. The registered enrollment target is 1,269 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT02215265, a Phase 3 study of Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer, is active but no longer recruiting, sponsored by Lisette Nixon.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,269 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objectives of the PATHOS study are: To assess whether swallowing function can be improved following transoral resection of HPV-positive OPSCC, by reducing the intensity of adjuvant treatment protocols. The aim is to personalise treatment, based on disease biology (HPV status and pathology findings), to optimise patient outcomes. To demonstrate the non-inferiority of reducing the intensity of adjuvant treatment protocols in terms of overall survival in the reduced intensity treatment arms.
Conditions Studied
Interventions
- DRUG Cisplatin
- RADIATION Postoperative radiotherapy
Study Locations (20)
Other
- Metro South Health - Brisbane
- Unicancer - Paris
- Vivantes Klinikum - Berlin
- Zentrum für Hals-, Nasen- und Ohrenheilkunde - Giessen
- Asklepios Kliniken - Hamburg
- Kath Marienkrankenhaus gGmbH - Hamburg
- Universitaetsklinikum des Saarlandes - Homburg
- Universitat Leipzig - Leipzig
- Ernst von Bergmann Klinikum - Potsdam
- Städtisches Klinikum Solingen - Solingen
- Universitätsklinikum Ulm - Ulm
- Royal United Hospitals Bath NHS Foundation Trust - Bath
- Queen Elizabeth Hospital - Birmingham
- Royal Blackburn Hospital - Blackburn
- Royal Sussex County Hospital - Brighton
- University Hospitals Bristol NHS Foundation Trust - Bristol
California
- Board of Trustees of the Leland Stanford Junior University - Redwood City
Florida
- Advent Health - Orlando
Texas
- MD Anderson Cancer Centre - Houston
Dorset
- University Hospitals Dorset NHS Foundation - Poole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,269 participants |
| Start Date | 2015-10 |
| Est. Completion | 2028-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02215265
The ClinicalTrials.gov registry entry for NCT02215265 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,269 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lisette Nixon, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cisplatin is the first listed.
NCT02215265 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02215265 about?
NCT02215265 is a clinical study titled "Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)". The main objectives of the PATHOS study are: To assess whether swallowing function can be improved following transoral resection of HPV-positive OPSCC, by reducing the intensity of adjuvant treatment protocols. The aim is to personalise treatment, based on disease biology (HPV status and pathology ...
What is the current status of trial NCT02215265?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,269 participants. The study started on 2015-10. Estimated completion is 2028-04.
What conditions does trial NCT02215265 study?
This clinical trial studies the following conditions: Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer.
What interventions are being tested in trial NCT02215265?
The interventions under investigation include: Cisplatin (DRUG), Postoperative radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT02215265?
This trial is sponsored by Lisette Nixon, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02215265 being conducted?
This trial has 20 study locations across California, Florida, Texas, Dorset. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.